Appili Therapeutics Inc. (OTCMKTS:APLIF – Get Free Report) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 1,900 shares, a decline of 99.0% from the September 30th total of 198,900 shares. Based on an average daily trading volume, of 232,400 shares, the days-to-cover ratio is presently 0.0 days.
Appili Therapeutics Stock Performance
Shares of APLIF opened at $0.03 on Friday. Appili Therapeutics has a 1 year low of $0.01 and a 1 year high of $0.05. The company’s 50 day simple moving average is $0.03 and its 200 day simple moving average is $0.03. The company has a market capitalization of $3.29 million, a price-to-earnings ratio of -0.90 and a beta of -0.48.
Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01).
Appili Therapeutics Company Profile
Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.
Further Reading
- Five stocks we like better than Appili Therapeutics
- How to Use Stock Screeners to Find Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Investors Need to Know to Beat the Market
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- The Most Important Warren Buffett Stock for Investors: His Own
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.